Home » Study: Novartis’ Afinitor Plus Hormonal Therapy Delays Breast Cancer Progression
Study: Novartis’ Afinitor Plus Hormonal Therapy Delays Breast Cancer Progression
A new study shows that the addition of everolimus (Afinitor tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative metastatic breast cancer who have been previously treated with an aromatase inhibitor delays disease progression compared to tamoxifen alone.
News Blaze
News Blaze
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May